ScreenerHero

PRFXPRF Technologies Ltd.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · painreform.com
0.9971USDMkt Cap: 3.03M $P/E: —

PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intra…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap3.03M $
Enterprise Value-2.52M $
Revenue (TTM)17.00K $
Gross Profit-53.00K $
Net Income (TTM)-5.02M $
Revenue/Share0.0260 USD
Last Price0.9971 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees6
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.08
PEG—
EV/EBITDA0.58
EV/Revenue-148.25
P/S178.93
P/B0.10
EPS (TTM)-7.47
EPS (Forward)-12.06
52W Range
0.980124% of range1.050
52W High1.050 USD
52W Low0.9801 USD
Profitability
Gross Margin-311.76%
Oper. Margin-16200.00%
EBITDA Margin0.00%
Profit Margin-29541.18%
ROE-58.78%
ROA-41.86%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.96M $
CapEx (TTM)2.00K $
FCF Margin-11777.94%
FCF Yield-66.02%
Net Debt-4.12M $
Net Debt/EBITDA0.95
Balance Sheet
Debt/Equity0.00
Current Ratio1.78
Quick Ratio1.75
Book Value/Sh10.29 USD
Cash/Share4.904 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:5
Split DateFeb 6, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.3.04M
Float844.37K
Insiders0.00%
Institutions6.69%
Short Interest
Short Ratio1.1d
Short % Float6.74%
Short % Out.6.74%
Shares Short205.00K
Short (prev mo.)127.70K
Technical
SMA 501.286 (-22.5%)
SMA 2002.750 (-63.7%)
Beta1.04
S&P 52W Chg21.00%
Avg Vol (30d)66.33K
Avg Vol (10d)691.19K
Technical Indicators
RSI (14)43.1
MACD-0.0712
MACD Signal-0.0792
MACD Hist.+0.0080
BB Upper1.167 USD
BB Middle1.044 USD
BB Lower0.9205 USD
BB Width23.66%
ATR (14)0.1208 USD
Vol Ratio (20d)0.15x